John D Quisel Gemini Therapeutics, Inc. (GMTX) insider trading activity

John D Quisel is Chief Executive Officer of Gemini Therapeutics, Inc. . Currently has a direct ownership of 184,128 shares of GMTX, which is worth approximately $4.49 Million. The most recent transaction as insider was on Dec 19, 2025, when has been sold 12,300 shares (Common Stock) at a price of $1.01 per share, resulting in proceeds of $12,423. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 184K

7.16% 3M change

155.5% 12M change

Total Value Held $4.49 Million

John D Quisel Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 19 2025	BUY Exercise of conversion of derivative security	$12,423 $1.01 p/Share	12,300 Added 6.26%	184,128 Common Stock
Dec 11 2025	SELL Open market or private sale	$3,698,000 $92.45 p/Share	40,000 Reduced 18.88%	171,828 Common Stock
Dec 11 2025	BUY Exercise of conversion of derivative security	$394,400 $9.86 p/Share	40,000 Added 15.88%	211,828 Common Stock
Sep 09 2025	BUY Exercise of conversion of derivative security	$10,100 $1.01 p/Share	10,000 Added 5.5%	171,828 Common Stock
Jul 09 2025	SELL Open market or private sale	$1,939,056 $55.72 p/Share	34,800 Reduced 17.7%	161,828 Common Stock
Jul 09 2025	BUY Exercise of conversion of derivative security	$343,128 $9.86 p/Share	34,800 Added 15.04%	196,628 Common Stock
Jul 03 2025	SELL Open market or private sale	$286,468 $55.09 p/Share	5,200 Reduced 3.11%	161,828 Common Stock

Jul 03 2025	BUY Exercise of conversion of derivative security	$51,272 $9.86 p/Share	5,200 Added 3.02%	167,028 Common Stock
Apr 07 2025	BUY Exercise of conversion of derivative security	$7,070 $1.01 p/Share	7,000 Added 4.15%	161,828 Common Stock
Feb 18 2025	SELL Open market or private sale	$304,228 $54.58 p/Share	5,574 Reduced 3.48%	154,828 Common Stock
Feb 10 2025	BUY Grant, award, or other acquisition	-	78,337 Added 32.81%	160,402 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	$10,100 $1.01 p/Share	10,000 Added 10.86%	82,065 Common Stock
Dec 30 2024	SELL Open market or private sale	$808,565 $62.14 p/Share	13,012 Reduced 15.29%	72,065 Common Stock
Dec 30 2024	BUY Exercise of conversion of derivative security	$128,298 $9.86 p/Share	13,012 Added 13.27%	85,077 Common Stock
Dec 23 2024	SELL Open market or private sale	$1,250,642 $63.1 p/Share	19,820 Reduced 21.57%	72,065 Common Stock
Dec 23 2024	BUY Exercise of conversion of derivative security	$52,523 $2.65 p/Share	19,820 Added 17.74%	91,885 Common Stock
Dec 16 2024	SELL Open market or private sale	$843,566 $65.95 p/Share	12,791 Reduced 15.07%	72,065 Common Stock
Dec 16 2024	BUY Exercise of conversion of derivative security	$12,918 $1.01 p/Share	12,791 Added 13.1%	84,856 Common Stock
Jul 08 2024	BUY Exercise of conversion of derivative security	$3,030 $1.01 p/Share	3,000 Added 4.0%	72,065 Common Stock
Jan 10 2024	BUY Grant, award, or other acquisition	-	66,365 Added 49.0%	69,065 Common Stock
Dec 29 2023	BUY Exercise of conversion of derivative security	$2,727 $1.01 p/Share	2,700 Added 50.0%	2,700 Common Stock

Also insider at

GOSS

Gossamer Bio, Inc. Healthcare

Director

JDQ

John D Quisel

Chief Executive Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GMTX shares.

Notify only if

Value

Insider Trading

Get notified when an Gemini Therapeutics, Inc. insider buys or sells GMTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Gemini Therapeutics, Inc.

Track Activities on GMTX

Account